PEMBROLIZUMAB (alone or when added to a regimen above)

DRUG2 trials

Sponsors

University of California, Irvine, The University of Hong Kong

Conditions

Gastroesophageal AdenocarcinomaNasopharyngeal Cancer RecurrentNasopharyngeal Cancinoma (NPC)

Phase 1

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

RecruitingNCT05733689

University of California, IrvineGastroesophageal Adenocarcinoma

Start: 2025-06-27End: 2027-06-01Target: 20Updated: 2026-03-10

Phase 2

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

Not yet recruitingNCT07129772

The University of Hong KongNasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC)

Start: 2025-11-01End: 2028-06-30Target: 53Updated: 2025-09-04

Related Papers

Response adapted neoadjuvant therapy in gastric cancer (RANT-GC): A phase Ib feasibility trial.

Journal of Clinical Oncology2026-01-10